Tesamorelin
12mg vial.
Tesamorelin is the heavy hitter of the GHRH family. FDA-approved specifically for reducing visceral (belly) fat. Clinically proven to significantly reduce trunk fat while preserving lean muscle mass.
Interested in Tesamorelin?
Our medical team will evaluate if this medication is right for you during your consultation.
Dosage & Administration
Daily subcutaneous injections for 12-26 weeks (extendable to 52 weeks with monitoring). Administered before bed like sermorelin.
Important: Like any prescribed medication, dosing varies from person to person. Always follow the dosage prescribed by your healthcare provider. Optimize 360 personalizes every protocol based on your labs, symptoms, and goals.
Side Effects
- Injection Site Reactions: More common than sermorelin — redness, itching, bumps at injection site.
- Joint Pain: Related to growth hormone effects.
- Headache: Mild.
- Swelling: Mild fluid retention possible.
Why Choose Optimize 360 for Tesamorelin
- Prescribed and monitored by Dr. Steve Farmer — 30+ years in hormone medicine
- Comprehensive lab work before prescribing — we never guess
- Sourced from licensed U.S. compounding pharmacies
- Transparent pricing — the price above is what you pay, no hidden fees
- Telehealth available nationwide — medications shipped to your door
- Unlimited messaging with your provider throughout treatment
Get Started Today
No memberships. No referral needed. Schedule your consultation and we'll take it from there.
Related
How Tesamorelin Works
Tesamorelin is an FDA-approved growth hormone-releasing hormone (GHRH) analog that stimulates the pituitary gland to produce and release growth hormone. It consists of the full 44-amino-acid GHRH sequence with an additional trans-3-hexenoic acid modification that increases its stability and potency compared to native GHRH and shorter analogs like sermorelin. Tesamorelin was originally approved for reduction of excess abdominal fat (lipodystrophy) in HIV-infected patients, but its GH-stimulating and fat-reducing properties have made it widely used in anti-aging and metabolic optimization.
Benefits & Clinical Evidence
Tesamorelin has the strongest clinical evidence base of any GHRH analog, including multiple randomized controlled trials. FDA-approval studies demonstrated significant reductions in visceral adipose tissue (VAT) — the metabolically dangerous deep abdominal fat — averaging 15-18% reduction over 26 weeks. Studies also show improvements in triglycerides, cholesterol ratios, and IGF-1 levels. Beyond fat reduction, patients commonly report improved body composition, enhanced sleep quality, better exercise recovery, and improved cognitive function. Research has also explored tesamorelin's potential cognitive benefits, with studies suggesting improved executive function in older adults.
Who Is a Good Candidate?
Tesamorelin is particularly well-suited for patients with excess visceral abdominal fat, age-related growth hormone decline, or those seeking a more potent GHRH analog than sermorelin. Patients who want an evidence-backed approach to GH optimization with FDA-grade clinical data behind it often prefer tesamorelin. It is also appropriate for patients focused on metabolic health — reducing visceral fat, improving lipid profiles, and supporting insulin sensitivity. Both men and women benefit, though it is most commonly prescribed for patients over 35 experiencing GH decline.
What to Expect: Treatment Timeline
Weeks 1-4: Improved sleep quality and subtle energy improvements. Months 1-3: Measurable increases in IGF-1 levels, early body composition changes, improved recovery. Months 3-6: Significant reduction in visceral abdominal fat (typically 15-18%), improved waist circumference, visible body composition improvements. Tesamorelin is injected subcutaneously once daily, typically before bedtime. Treatment courses usually run 3-6 months with lab monitoring of IGF-1 and metabolic markers. Available at Optimize 360 from $262.50/vial.
Side Effects & Safety
Common side effects include injection site reactions (redness, itching, swelling), joint pain, and peripheral edema — similar to other GH-stimulating therapies. These are generally mild and often resolve with continued use. Because tesamorelin stimulates natural GH production (rather than replacing it), the risk of GH excess is modulated by the body's own feedback mechanisms. Patients with active cancer should not use GH-stimulating therapies. Regular monitoring of IGF-1, fasting glucose, and HbA1c is recommended, as GH can affect insulin sensitivity.
Frequently Asked Questions
A: Tesamorelin is a more potent GHRH analog than sermorelin. It contains the full 44-amino-acid GHRH sequence (vs. sermorelin's 29) with an additional stabilizing modification. Clinical data shows tesamorelin produces larger increases in GH and IGF-1 and has FDA-approval-level evidence for visceral fat reduction. It is typically more expensive but may deliver more robust results.
A: Studies show that visceral fat tends to gradually reaccumulate after stopping tesamorelin, though the rate varies by individual. Maintaining results long-term typically requires ongoing therapy, lifestyle optimization (diet and exercise), or periodic treatment cycles. Your provider will help you develop a sustainable plan.
A: Yes. Tesamorelin (brand name Egrifta) is FDA-approved for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Its use for age-related GH decline and metabolic optimization is considered off-label but is supported by the same clinical data that earned FDA approval. At Optimize 360, tesamorelin is available as a compounded formulation prescribed by licensed providers.
Also Available